2015 American Transplant Congress
Unrecognized Synchronous Hepatocellcular Carcinoma Lesions in Explanted Liver Transplant Specimens
Introduction: Liver resection for early-stage hepatocellular carcinoma (HCC) is limited by high surgical risk in cirrhotics and high rates of intrahepatic recurrence. We postulated that…2015 American Transplant Congress
Characteristics and Outcomes of Patients With Incidental Hepatocellular Carcinoma Detected in the Explanted Liver Following Transplant
Introduction: Despite pre-operative cross-sectional imaging, incidental hepatocellular carcinoma (iHCC) is sometimes diagnosed upon histological examination of the liver explant following transplantation for another indication. Whilst…2015 American Transplant Congress
Independent Prognostic Factors for Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: UNOS Population Study
Background: The impact of regional differences in bridging locoregional therapy (LRT) use and wait times on overall survival (OS) in hepatocellular carcinoma (HCC) patients undergoing…2015 American Transplant Congress
Longitudinal Trends in Wait Times and Use of Bridging Locoregional Therapies in Hepatocellular Carcinoma Patients undergoing Orthotopic Liver Transplantation: UNOS Population Study
Background: Trends in bridging locoregional therapies (LRT) and wait times for patients with hepatocellular carcinoma (HCC) undergoing orthotopic liver transplantation (OLT) have not been investigated…2015 American Transplant Congress
Refinement of Non-Invasive Diagnostic Criteria to Differentiate Tumor from Bland Portal Vein Thrombosis Before Liver Transplant in Patients With Hepatocellular Carcinoma
University of California San Francisco, San Francisco, CA.
Differentiating tumor vs bland portal vein thrombosis (PVT) is essential in determining liver transplant (LT) candidacy for patients with hepatocellular carcinoma (HCC). The primary aim…2015 American Transplant Congress
SBRT(Stereotactic Body Radiotherapy) to Bridge or Down-Size HCC for Liver Transplantation
Twenty seven (27) pts with HCC and cirrhosis have been treated with SBRT with intent for liver transplantation since 2010 at Allegheny Health Network. Nineteen…2015 American Transplant Congress
The Extended Toronto Criteria for Transplantation for Hepatocellular Carcinoma. A Validation Study
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
Liver transplant (LT) listing criteria for patients with hepatocellular cancers (HCC) that exceed the Milan criteria are still controversial. At the University of Toronto, we…2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…2015 American Transplant Congress
Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation
Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…2015 American Transplant Congress
Impact of Everolimus On the Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation When Used in Early Stage: A Single Center Prospective Study
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Background:Liver transplantation is only treatment for unresectable hepatocellular carcinoma (HCC). However, postoperative immunosuppression may act as an additional risk factor for tumour recurrence. Antineoplastic role…
American Transplant Congress abstracts